GlassScriptPhysician profile
Dharmen J Patel
NPI 1669577797
$20,754.77
in general payments reported to CMS, 2019-2025
81 companies · $3,056 in 2025
The $3,056 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,762 · 2020: $2,668 · 2021: $3,072 · 2022: $3,308 · 2023: $3,336 · 2024: $3,553 · 2025: $3,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,666 · Education: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,665.97 |
| Education | $279.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,652.93 | 2019-2025 | Darzalex, Tecvayli, Erleada |
| Merck Sharp & Dohme LLC | $1,434.18 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $1,329.67 | 2019-2025 | Enhertu, Tagrisso, Imfinzi |
| Novartis Pharmaceuticals Corporation | $1,061.50 | 2019-2025 | Kisqali |
| Amgen INC. | $967.28 | 2019-2023 | Xgeva, Vectibix, Nplate |
| Pfizer INC. | $879.91 | 2019-2025 | |
| Daiichi Sankyo INC. | $857.43 | 2020-2025 | Enhertu, Injectafer, Datroway |
| Incyte Corporation | $787.12 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Genzyme Corporation | $768.37 | 2019-2025 | |
| Celgene Corporation | $642.35 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Gilead Sciences, INC. | $626.59 | 2019-2025 | Trodelvy |
| Astellas Pharma US INC | $514.54 | 2019-2025 | Padcev, Vyloy |
| Glaxosmithkline, LLC. | $495.77 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Genentech USA, INC. | $482.01 | 2020-2025 | Tecentriq, Polivy, Perjeta |
| Eisai INC. | $470.33 | 2019-2025 |
Show all 81 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dharmen Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.